Search is Powered by Google
Cancer / Oncology News

Nanocenter Offers Promising Non-Invasive Cancer Treatment

Main Category: Cancer / Oncology
Article Date: 29 Oct 2008 - 1:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:5 stars

5 (3 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

A team of scientists at Arkansas Nanotechnology Center at UALR (the University of Arkansas at Little Rock) has developed what promises to be a non-invasive method of eradicating cancer cells while reducing the life-threatening side effects of chemotherapy and radiation.

The new technique, described in the current issue of the journal Nanotechnology, was developed by a team led by Dr. Alexandru Biris, assistant professor of applied science and chief scientist at the Nanotechnology Center. Working in collaboration with the University of Arkansas for Medical Sciences, the team successfully killed more than 98 percent of the cervical cancer cells used in the study.

The technique introduces nano-sized cobalt particles encased in graphitic carbon layers inside the cells and thermally activates them by using radio frequency radiation. By applying low radio frequency radiation used in some electronic or electromagnetic devices the magnetic portion in the nanoparticles heats up the cancerous cells, destroying them.

The procedure promises a non-invasive method of eradicating cancer cells while reducing the life-threatening side effects of chemotherapy and radiation.

The technique is described in their new research paper, Cobalt Nanoparticles Coated with Graphitic Shells as Localized Radio Frequency Absorbers for Cancer Therapy.

"We have demonstrated that using a combination of a low frequency, low power radio frequency radiation which has a high penetration ability in human tissue with graphitic magnetic composite nanoparticles could prove an excellent means of raising the temperature at the cellular level above the threshold required for DNA fragmentation or protein denaturation," Biris said. "The result is death of the cells. This technique is less invasive and possesses higher efficiency for targeting localized cells. It also has the potential to reduce the side effects associated with traditional cancer therapies."

With approved research protocols, UAMS scientists are expanding on previous work involving use of nanostructural materials for killing tumors with lasers. Using this method, the nanomaterials are introduced through the bloodstream to be activated with radio frequency energy once they are in the tumors.

"We believe this method is extremely promising for killing cancer cells," said Dr. Vladmir Zharov, professor and director of the Phillips Classic Laser Laboratories in the UAMS Winthrop P. Rockefeller Cancer Institute. "We are working now to move this technology toward clinical trials with the ultimate goal of achieving a safe, effective procedure that leaves a patient cancer free."

Biris, a native of Romania who earned a Ph.D. in applied science at UALR in 2004, said the delivery of the encased nanoparticle to tumors will also be explored by binding them to cancer-specific antibodies.

By using antibodies or other nanoparticle bioconjugations the coupling of two substance the nanoparticles are expected to find the cancer cells even in advanced cases, including places that before now have been considered inoperable. The nanoparticles can also find undiagnosed micrometastasis, or the spread of cancer cells from the primary site with the secondary tumors too small to be detected clinically.

"This research has extended the understanding of the mechanisms that are responsible for effective nanoparticle targeting and eventually the death of cancer cells," Zharov said.

The team's work is helping to explain the mechanism that is responsible for the death of the cells by figuring out the localized thermal damages such as protein denaturation and DNA fragmentation associated with the process. The finding can be applied to bacteria, viruses, or other biological systems.

Members of the research team working with Biris are:

-- Yang Xu, Meena Mahmood, Zhongrui Li, and Enkeleda Dervishi, Nawab Ail, and Viney Saini, all of all of the Nanotechnology Center and Department of Applied Science at UALR.

-- Vladimir P. Zharov' group: Ekaterina Galanzha and Evgeny Shashkov, the Philips Classic Laser Laboratories at UAMS.

-- Steve Trigwell of ASRC Aerospace, NASA's Electrostatic and Surface Physics Laboratory at Kennedy Space Center in Florida.

-- Alexandru R. Biris and Dan Lupu of the National Institute for Research and Development of Isotopic and Molecular Technologies, Cluj Napoca, Romania.

-- Dorin Boldor of Louisiana State University's AgCenter, Biological and Agricultural Engineering Department in Baton Rouge, LA.

To read Biris' paper, visit http://www.iop.org/EJ/journal/Nano.

University of Arkansas at Little Rock
2801 S University
Little Rock
AR 72204-1099
United States
http://ualr.edu/www




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...